spacer
home > ebr > spring 2009 > dispersions deliver results
PUBLICATIONS
European Biopharmaceutical Review

Dispersions Deliver Results

 

Low-solubility, high-permeability compounds make up nearly one-third of all active pharmaceutical ingredients (APIs) in early development. For many compounds in this class, oral absorption can be achieved by enhancing solubility using solubilisation technologies. This article is an overview of current options in solid form solubilisation technologies, including several novel platforms that are based on nanocrystals and drug/polymer solid amorphous dispersions. The platforms discussed are spray-dried dispersions (SDDs), nanoadsorbates and crystallised spray-dried dispersions (CSDDs). Strategies are described to guide rational selection of the optimum technology for solubility enhancement.

Poor oral bioavailability due to the low aqueous solubility of potential drug candidates is an increasingly common challenge facing the pharmaceutical industry (1). Nearly one-third of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in economic and therapeutic opportunity (2). Although they may not fit the ‘rule of five’, many of these low-solubility compounds – which fall into Class II of the Biopharmaceutics Classification System (BCS) – have the potential to be safe and efficacious, so it is critical that further development is not halted by solubility limitations (3).

In response to this problem, multiple drug-delivery technologies have been advanced in an attempt to solubilise such molecules in order to enhance their oral bioavailability. Solubilisation technologies can improve oral absorption of BCS Class II compounds by:

  • Increasing dissolution rate
  • Increasing concentration of dissolved drug (above the equilibrium concentration of the solubility of bulk crystalline drug)
  • Maintaining the enhanced dissolved drug concentration

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer

Dr David T Vodak is a Senior Research Chemist and Group Leader at Bend Research Inc, a private research and development laboratory in Bend, Oregon. David holds a PhD in materials chemistry from the University of Michigan-Ann Arbor and a BA in Chemistry from Willamette University in Salem, Oregon. After completing his post-doctoral work at the Scripps Research Institute in La Jolla, California, David joined Bend Research Inc, where he has worked on novel technology development. His areas of expertise are the research and development of novel pharmaceutical drug-delivery systems for the delivery of low-solubility compounds.

Dr Dwayne T Friesen is the Vice President of Research at Bend Research Inc. Dwayne holds a PhD in physical chemistry from Oregon State University in Corvallis, Oregon, and a BS in Chemistry from California State College – Bakersfield. He holds 44 US patents and has 15 scientific publications. Dwayne directs the research and development for novel drug-delivery systems and pharmaceutical formulations.

spacer
David T Vodak
spacer
spacer
spacer
Dwayne T Friesen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement